Long-term treatment with flupentixol results of a post-marketing surveillance study

被引:2
作者
Messer, T. [1 ]
Glaser, T. [2 ]
Landen, H. [2 ]
Schmauss, M. [1 ]
机构
[1] Reg Hosp Augsburg, Clin Psychiat & Psychotherapy, Augsburg, Germany
[2] Bayer Vital GmbH, Leverkusen, Germany
关键词
flupentixol; schizophrenia; antipsychotics; neuroleptics; treatment; tolerability; QUALITY-OF-LIFE; ANTIPSYCHOTIC-DRUGS; RELAPSE PREVENTION; FOLLOW-UP; SCHIZOPHRENIA; RISPERIDONE; OLANZAPINE; THERAPY; 2ND-GENERATION; HALOPERIDOL;
D O I
10.1177/0269881108091879
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Schizophrenia is one of the most expensive illnesses. Antipsychotics are an essential component of the acute and preventative treatment of this illness, and long-term treatment is necessary to decrease the risk of psychotic relapse. The efficacy and tolerability of flupentixol was evaluated in a post-marketing surveillance study (PMS) in schizophrenic patients receiving long-term treatment in routine clinical practice. Psychiatrists in office practice treated patients for approximately 10 weeks, with a subsequent follow-up period of up to 18 months. We here report on the follow-up period in 128 patients. The benefit for schizophrenic patients increased with the treatment duration of flupentixol as documented by the Clinical Global Impression (CGI). Subjective quality of life improved during the first study period, and this remained stable in the follow-up period. No increase in body weight was observed during the study. The relapse rate was much lower than in other studies. Anticholinergic medication was necessary for 22.7% of the patients at any time. More than 70% of the psychiatrists involved evaluated the treatment as very good or good. The results of this study suggest that flupentixol is a potent and safe antipsychotic for the long-term treatment of schizophrenia in routine clinical practice.
引用
收藏
页码:805 / 813
页数:9
相关论文
共 42 条
[1]   Systematic meta-review of depot antipsychotic drugs for people with schizophrenia [J].
Adams, CE ;
Fenton, MKP ;
Quraishi, S ;
David, AS .
BRITISH JOURNAL OF PSYCHIATRY, 2001, 179 :290-299
[2]   Cost of disorders of the brain in Europe [J].
Andlin-Sobocki, P ;
Jönsson, B ;
Wittchen, HU ;
Olesen, J .
EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 :1-+
[3]   Smoking impact on CYP1A2 activity in a group of patients with schizophrenia [J].
Bozikas, VP ;
Papakosta, M ;
Niopas, L ;
Karavatos, A ;
Mirtsou-Fidani, V .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 (01) :39-44
[5]   Recent trends in antipsychotlic combination therapy of schizophrenia and schizoaffective disorder: Implications for state mental health policy [J].
Clark, RE ;
Bartels, SJ ;
Mellman, TA ;
Peacock, WJ .
SCHIZOPHRENIA BULLETIN, 2002, 28 (01) :75-84
[6]   SENSORIMOTOR AND COGNITIVE PERFORMANCE OF SCHIZOPHRENIC INPATIENTS TREATED WITH HALOPERIDOL, FLUPENTIXOL, OR CLOZAPINE [J].
CLASSEN, W ;
LAUX, G .
PHARMACOPSYCHIATRY, 1988, 21 (06) :295-297
[7]   A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia [J].
Csernansky, JG ;
Mahmoud, R ;
Brenner, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (01) :16-22
[8]   A meta-analysis of the efficacy of second-generation antipsychotics [J].
Davis, JM ;
Chen, N ;
Glick, ID .
ARCHIVES OF GENERAL PSYCHIATRY, 2003, 60 (06) :553-564
[9]   Antipsychotic medication adherence: Is there a difference between typical and atypical agents? [J].
Dolder, CR ;
Lacro, JP ;
Dunn, LB ;
Jeste, DV .
AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (01) :103-108
[10]  
GARTENMAIER A, 1998, FLUPENTIXOL TYPISCHE, P35